Get started
Author

Ma'An Muhsin

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
2024 · Robert S. Rosenson, Daniel Gaudet, et al. · New England Journal of Medicine · 213
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
2024 · Gerald F. Watts, Robert S. Rosenson, et al. · New England Journal of Medicine · 177
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
2025 · Frederick J Raal, Jean Bergeron, et al. · The Lancet Diabetes & Endocrinology · 24
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia
2024 · Gerald F. Watts, Robert A. Hegele, et al. · Circulation · 6
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
2024 · D G Gaudet, R S Rosenson, et al. · European Heart Journal · 4
Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3
2025 · Miriam Larouche, Diane Brisson, et al. · JIMD Reports · 2
PDF
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
2025 · G Watts, R S Rosenson, et al. · European Heart Journal · 2
Zodasiran (ARO-ANG3), an investigational RNAi therapeutic, demonstrates profound and durable reductions in LDL-cholesterol, apolipoprotein B, and ANGPTL3 in patients with HoFH; gateway final results
2025 · Frederick Raal, Jean Bergeron, et al. · Atherosclerosis · 2
PDF
Abstract 4363704: YOSEMITE Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Zodasiran Efficacy and Safety in Adolescents and Adults with Homozygous Familial Hypercholesterolemia
2025 · Frederick Raal, Ran Fu, et al. · Circulation · 1
Palisade: Plozasiran Decreases the Risk of Acute Pancreatitis and May Improve Quality of Life in Familial Chylomicronemia Syndrome
2025 · Gerald F Watts, Robert A Hegele, et al. · American Journal of Preventive Cardiology · 1
Abstract 4139852: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial
2024 · Christie Ballantyne, Gerald Watts, et al. · Circulation · 1
Zodasiran silences hepatic ANGPTL3 leading to deep and durable reductions in atherogenic lipids and lipoproteins in mixed dyslipidemia patients: Final results from arches-2, double-blind period
2024 · Robert Rosenson, Daniel Gaudet, et al. · Atherosclerosis · 1
PDF
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
2025 · R S Rosenson, D Gaudet, et al. · European Heart Journal
Palisade: Plozasiran decreases the risk of Acute Pancreatitis (AP) and may improve Quality of Life (QOL) in Familial Chylomicronemia Syndrome (FCS)
2025 · Gerald Watts, Robert Hegele, et al. · Atherosclerosis
PDF
Plozasiran decreases the risk of acute pancreatitis and may improve quality of life in familial chylomicronemia syndrome
2025 · Robert Hegele, Robert Rosenson, et al. · Journal of clinical lipidology
Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results
2024 · Christie Ballantyne, Szilard Vasas, et al. · Atherosclerosis
PDF
Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results
2024 · Daniel Gaudet, Denes Pall, et al. · Atherosclerosis
PDF
Works count: 17
Citation count: 432
H-index: 4
I10-index: 3
Year
Topic
Type